JP2022522486A5 - - Google Patents

Info

Publication number
JP2022522486A5
JP2022522486A5 JP2021551785A JP2021551785A JP2022522486A5 JP 2022522486 A5 JP2022522486 A5 JP 2022522486A5 JP 2021551785 A JP2021551785 A JP 2021551785A JP 2021551785 A JP2021551785 A JP 2021551785A JP 2022522486 A5 JP2022522486 A5 JP 2022522486A5
Authority
JP
Japan
Application number
JP2021551785A
Other languages
Japanese (ja)
Other versions
JP7565292B2 (ja
JPWO2020177587A5 (https=
JP2022522486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/076723 external-priority patent/WO2020177587A1/zh
Publication of JP2022522486A publication Critical patent/JP2022522486A/ja
Publication of JP2022522486A5 publication Critical patent/JP2022522486A5/ja
Publication of JPWO2020177587A5 publication Critical patent/JPWO2020177587A5/ja
Application granted granted Critical
Publication of JP7565292B2 publication Critical patent/JP7565292B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021551785A 2019-03-01 2020-02-26 脂肪性肝疾患および/または脂肪性肝炎の処置方法 Active JP7565292B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019076688 2019-03-01
CNPCT/CN2019/076688 2019-03-01
PCT/CN2020/076723 WO2020177587A1 (zh) 2019-03-01 2020-02-26 治疗脂肪性肝病和/或脂肪性肝炎的方法

Publications (4)

Publication Number Publication Date
JP2022522486A JP2022522486A (ja) 2022-04-19
JP2022522486A5 true JP2022522486A5 (https=) 2023-03-06
JPWO2020177587A5 JPWO2020177587A5 (https=) 2023-03-06
JP7565292B2 JP7565292B2 (ja) 2024-10-10

Family

ID=72337009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021551785A Active JP7565292B2 (ja) 2019-03-01 2020-02-26 脂肪性肝疾患および/または脂肪性肝炎の処置方法

Country Status (11)

Country Link
US (1) US12485108B2 (https=)
EP (1) EP3932404A4 (https=)
JP (1) JP7565292B2 (https=)
KR (1) KR102906316B1 (https=)
CN (1) CN113490493B (https=)
AU (1) AU2020230574B2 (https=)
BR (1) BR112021017354A2 (https=)
CA (1) CA3132228A1 (https=)
IL (1) IL285989B2 (https=)
TW (1) TWI852999B (https=)
WO (1) WO2020177587A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539276A (ja) * 2020-08-31 2023-09-13 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用
CN113135900B (zh) * 2021-03-12 2022-05-24 中山大学 吲哚嘧啶类化合物及其合成方法和应用
IL311447A (en) * 2021-09-18 2024-05-01 Beijing Tide Pharmaceutical Co Ltd A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof
KR20240095429A (ko) * 2021-11-16 2024-06-25 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rock2 억제제의 나노결정 제제 및 이의 제조방법
CA3254208A1 (en) * 2022-03-14 2023-09-21 Purdue Research Foundation SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION AND METHODS OF USE
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL325831A (en) 2023-07-17 2026-03-01 Graviton Bioscience Bv ROCK2 inhibitor formulations for central nervous system disorders
CN117122602B (zh) * 2023-09-26 2026-03-20 赣南创新与转化医学研究院 化合物在制备治疗和/或预防脂肪肝病及相关疾病的药物中的用途
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040499A2 (en) * 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2018039539A1 (en) 2016-08-26 2018-03-01 Lycera Corporation Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
CN110582489B (zh) 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10323023B2 (en) * 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2022522486A5 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)